Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation

Status Active, not recruiting

Clinical Trial Summary

Investigators intend to evaluate the efficiency of Radiofrequency ablation (RFA) therapy to treat papillary thyroid carcinoma.

Clinical Trial Description

Investigators plan to identify patients with small papillary thyroid carcinoma and subject such patients to radiofrequency ablation (RFA) therapy. Following RFA procedure patients will be monitored to study the changes in primary tumor volume, development of lymph node involvement, development of distant metastasis and changes in serum thyroid hormone levels. Investigators will also assess the stability of these changes (need for repeat therapy) and the safety of the RFA procedure. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04129411
Study type	Interventional
Source	Mayo Clinic
Contact
Status	Active, not recruiting
Phase	N/A
Start date	June 15, 2020
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01441154` - Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
Active, not recruiting	`NCT04544111` - PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer	Phase 2
Recruiting	`NCT03469011` - A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.	Phase 1
Recruiting	`NCT05752669` - Oxidative Stress and Mitochondrial TERT in Papillary Thyroid Cancer.
Recruiting	`NCT04076514` - The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma
Completed	`NCT06439745` - More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
Active, not recruiting	`NCT01723202` - Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer	Phase 2
Recruiting	`NCT05500508` - Oral AMXT 1501 Dicaprate in Combination With IV DFMO	Phase 1/Phase 2
Active, not recruiting	`NCT02568267` - Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)	Phase 2
Unknown status	`NCT02140476` - Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy	N/A
Recruiting	`NCT06286631` - Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale
Completed	`NCT06325787` - Image-guided Thermal Ablation vs. Lobectomy for Solitary Papillary Thyroid Microcarcinoma	N/A
Terminated	`NCT01974284` - Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma	N/A
Active, not recruiting	`NCT00984191` - Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid	N/A
Active, not recruiting	`NCT04731467` - A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05668962` - Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC	Phase 2
Completed	`NCT02178345` - Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer
Not yet recruiting	`NCT06133374` - Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples
Completed	`NCT03470259` - Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging	Phase 1
Recruiting	`NCT03899792` - A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors	Phase 1/Phase 2